1. Who can I contact for more information?

Please don’t hesitate to contact us by email at openinnovation@seegene.com.

2. When can I apply? 

Applications for the award will open on September 4, 2023 and close on October 31, 2023 11:59pm GMT.

3. Who can apply?

Applicants should be employed by or affiliated with a university, research institute or any other similar organization capable of performing a clinical study. Full details are available in the Before you apply page.

4. How do I apply?

Applications must be submitted online at: openinnovation.submittable.com 

5. Do applicants need to be nominated?

No, applicants for each award need to submit their own applications. However, you can recommend candidates to apply for the award and we will send an email with the link for application.

6. When will I know if I have been shortlisted?

All shortlisted applicants will be announced on January 12, 2024 and the awardees on March 15, 2024.

7. Will I receive feedback on my proposal?

Unfortunately, we cannot provide individual feedback on applications.

8. What are the assessment criteria and how will proposals be reviewed?

Applications will be reviewed by Seegene’s review panel consisting of molecular diagnostics experts from both R&D and non-R&D departments. For each project, a shortlist of applications will be initially compiled and announced. Within the shortlist, the awarded applications will be selected by the review panel based on the criteria below.

Assessment criteria:

  • Understanding of molecular diagnostic product development process and product design for the proposed project
  • Clinical study design and plan
  • Potential scientific or societal impact
  • Applicant/team qualifications and project budget feasibility
  • Access to clinical samples and specimens for the proposed development study plan

Awardee for each project will be selected based fully on the voting of the review panel. 

Full details are available in the ‘Before you apply’ page.

9. What are the research disciplines included in the scope of the award?

This Open Innovation Program is focused on conducting clinical studies of products designed to diagnose infectious diseases, vector-borne disease, and drug resistances. Please refer to the project list.

10. If I submit the application, can I edit it before the deadline?

Yes, you can request to edit your submitted applications before the deadline.

11. If my application is not selected, can I resubmit my proposal?

Yes, resubmission will be available to those who qualify during the next application period.

12. How much is the award? 

The awardee will receive up to 600,000 USD per project. However, as the budget may vary between countries and regions, reflecting differences in the number of samples required for each product, management costs and the personnel. The total budget will be determined during the contract after the awardee has been announced. The budget will be confirmed later, and the budget details provided 'Before you apply' are only an example for your reference.

13. How many individual projects can each applicant submit in their proposal? 

Applications are open for fifteen projects across infectious and vector-borne diseases, as well as in the detection of drug-resistant pathogens. Each applicant may submit a proposal for up to three projects with the exception of applications that include the ‘Respiratory Panel 1/2/3/4’, in which applicants may submit up to four projects in their proposal.

14. How many co-investigators can I include? Can co-investigators from a different institution participate?

There is no limit to the number of co-investigators and affiliations. The awardee must set the amount of personnel expenses within the total budget provided by the award.

15. Who owns the results of the research?

The entire right, title and interest in and to any and all Inventions, including but not limited to the Reports (“Studies Results”) and Seegene Product, shall be the property of Seegene, and to the extent that the Institute invented, or made contributions in inventing, any Inventions in the performance of Institute’s obligations under this Agreement, to the maximum extent permitted by law, shall be considered “works made for hire,” and therefore, all right, title and interest therein will vest exclusively in Seegene. For details, refer to '6. OWNERSHIP OF INVENTIONS AND STUDIES RESULTS' in the sample 'Services Agreement' document.

16. If our project is finished, can we publish the case study elsewhere?

Yes, but the Institute shall provide Seegene with a pre-publication manuscript or presentation script at least fourteen (14) days prior to any planned submission of the manuscript to a publisher or planned date of presentation for Seegene to review and approve. For details, refer to 5. USE AND PUBLICATION OF STUDY DATA in the sample 'Services Agreement' document.

17. Who is responsible for obtaining ethical approval?

The applicant is responsible for complying with all the necessary ethical, legal, and regulatory requirements and other applicable guidelines in order to conduct the clinical study.

18. What are the responsibilities and obligations of the awardee?

The awardee must carry out the proposed studies in their application and are obligated to provide information related to the activities supporting the development of project product upon Seegene's request. For details, refer to the sample 'Services Agreement' document.

19. How are Seegene and Springer Nature involved?

Beginning in H2 of 2023, as the first step of collaboration for the Seegene OneSystem™ Business, Seegene and Springer Nature launched the Open Innovation Program. Seegene Inc. funds the research award and Springer Nature is responsible for the promotion of the Open Innovation Program to the global scientific community. The Open Innovation Program seeks researchers who will conduct studies supporting the products developed by Seegene. Springer Nature employees have no influence in funding decisions. 

20. What materials and equipment are provided through the Open Innovation Program?

Seegene will provide the awardee equipment-related consumables (tips, tubes, waste bags, PCR tubes, caps), reagents (extraction reagents and Seegene PCR reagent kits) and the free rental of necessary equipment (CFX96, STARlet, NIMBUS) throughout the duration of the project. Full details are available in the Before you apply page.

21.How much is the consulting fee and how often is it made?

The awardee will provide consulting services to Seegene when necessary, and the consulting fees will be included in the applicant's personnel expenses. Full details are available in the 'Terms and Conditions' document.

22. If our project is finished, what is the next step?

After the completion of the proposed study, Seegene will seek to commercialize the assay if feasible.

23. How many clinical specimens do we need to have in preclinical study and clinical study?

For each product, the number of clinical specimens may vary based on the study plan and the requirements for market approval that the product seeks, but the recommended number for the projects in general is as follows.

  • Preclinical study: Positive 20 ea (per target) + negative 50 ea
  • Clinical study: Positive 40 ea (per target)+ negative 70 ea (In the case of low-prevalence target analytes: positive ~20 ea/target) 

Full details are available in Appendix 2 of the 'Application form' document. You may still apply even if you do not meet all the requirements stated above.